/

PCVX

Vaxcyte, Inc.Open

68.33−2.32 −3.28%USD

NasdaqGS · as of Oct 13, 11:22 ET · 15m delay

Open

70.28

Prev close

70.65

Day range

68.2571.09

52-week range

39.8790.75

Volume

490.35K0.28×

Mkt cap

10.75B

P/E ttm

—

Fwd P/E

-9.67

EPS ttm

-7.62

Div yield

0.00%

Earnings

—

From 52w high

−24.71%

Price Chart

Yahoo Finance · delayed

PCVXOct 13, 2026O 70.28H 71.09L 68.25C 68.33−2.32 (−3.28%)Vol 490.35K

SMA 5060.57
SMA 20055.95

1Y change +56.36% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PCVX Vaxcyte, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.44%
1 month: +14.90%
3 months: +21.56%
6 months: +8.88%
Year to date: +48.09%
1 year: +55.97%

Valuation & ownership

Market cap: 10.75B
Enterprise value: 9.14B
P/E (ttm): —
Forward P/E: -9.67
PEG ratio: —
Price / book: 3.59
Price / sales (ttm): —
EV / EBITDA: -7.96
EPS (ttm): -7.62
EPS (forward): -7.07
Beta (5y monthly): 1.23
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 157.39M
Float: 137.11M
Short % of float: 11.68%
Short ratio (days): 12.15
Held by insiders: 0.49%
Held by institutions: 110.92%
Avg volume (3m): 1.78M
50-day average: 60.27
200-day average: 55.85
52-week change: +55.97%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 59.2
vs 50-day SMA: +12.81%
vs 200-day SMA: +22.13%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.83%
Realised vol (20d, ann.): 114.4%
From 52-week high: −24.71%
From 52-week low: +71.38%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.27 on a 1 (strong buy) – 5 (sell) scale

Mean target

117.30

+71.67% implied

Low 75.00Median 121.00High 163.00

Recommendation trend

Now10 / 1 / 0
1m ago / 1 /

DES

About Vaxcyte, Inc.

Yahoo Finance profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 507
Headquarters: San Carlos, CA, United States
Website: vaxcyte.com
Officers: Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director
Mr. Andrew L. Guggenhime M.B.A. President & CFO
Mr. James T. Wassil M.B.A., M.S.

SEAS

Seasonality · PCVX

2020–2026 · monthly returns

Strongest month Aug +13.26%Weakest month Mar −15.24%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	16.1	15.3	-5.9	-1.5	-10.2	13.1	-7.0	12.3	-6.3	20.1			+48.1%
2025	7.9	-17.3	-48.3	-5.1	-9.3	0.1	4.4	-9.3	17.0	25.7	9.6	-7.0	−43.6%
2024	13.7	3.4	-7.5	-11.4	16.1	7.5	4.5	2.4	41.5	-6.9	-11.3	-13.2	+30.4%
2023	-5.4	-9.7	-8.5	14.3	15.6	0.8	-3.8	8.0	-1.8	-5.6	7.6	21.3	+31.0%
2022	-20.0	21.7	4.2	0.2	-0.9	-9.3	6.1	13.3	-8.3	81.7	5.6	4.1	+101.6%
2021	-7.7	-4.0	-16.2	-6.0	13.5	6.8	-3.7	21.0	-3.3	-7.8	-12.9	16.7	−10.5%
2020							-0.6	44.2	9.1	-24.3	-14.1	-17.2	−15.9%

INSD

Insider Activity · PCVX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

176.1K shares

Sells, 6 months

166.1K shares

Net shares

+10K

Net change in insider shares

+1.40%

Date	Insider	Transaction	Shares	Value
Oct 4, 2026	Wassil JamesChief Operating Officer	Sale at price 86.74 per share.	18K	$1.56M
Oct 4, 2026	Wassil JamesChief Operating Officer	Conversion of Exercise of derivative security at price 5.35 per share.	18K	$96.30K
Oct 4, 2026	Cowan ElviaOfficer	Sale at price 86.74 per share.	19K	$1.65M
Oct 4, 2026	Cowan ElviaOfficer	Conversion of Exercise of derivative security at price 25.92 per share.	19K	$492.48K
Sep 8, 2026	Wassil JamesChief Operating Officer	Sale at price 59.52 - 61.16 per share.	2.7K	$163.86K
Sep 3, 2026	Jodar LuisOfficer	Stock Award(Grant) at price 0.00 per share.	52.6K	—
Aug 31, 2026	Wassil JamesChief Operating Officer	Sale at price 60.89 - 61.48 per share.	3.5K	$212.35K
Aug 31, 2026	Wassil JamesChief Operating Officer	Conversion of Exercise of derivative security at price 5.35 per share.	2.3K	$12.04K
Aug 4, 2026	Dhaliwal Harpreet S.Officer	Sale at price 55.00 per share.	17K	$935.07K
Aug 4, 2026	Dhaliwal Harpreet S.Officer	Conversion of Exercise of derivative security at price 24.79 per share.	17K	$421.43K
Aug 2, 2026	Guggenhime AndrewPresident	Sale at price 53.76 - 54.18 per share.	10K	$538.88K
Aug 2, 2026	Guggenhime AndrewPresident	Conversion of Exercise of derivative security at price 5.35 per share.	10K	$53.50K
Aug 2, 2026	Wassil JamesChief Operating Officer	Sale at price 53.50 - 54.09 per share.	2.3K	$121.19K
Aug 2, 2026	Wassil JamesChief Operating Officer	Conversion of Exercise of derivative security at price 5.35 per share.	2.3K	$12.04K
Jul 26, 2026	Pickering Grant EChief Executive Officer	Sale at price 55.52 - 55.96 per share.	18.2K	$1.01M
Jul 26, 2026	Pickering Grant EChief Executive Officer	Conversion of Exercise of derivative security at price 2.03 per share.	16.2K	$32.88K
Jul 5, 2026	Guggenhime AndrewPresident	Sale at price 57.16 - 57.76 per share.	10K	$572.84K
Jul 5, 2026	Guggenhime AndrewPresident	Conversion of Exercise of derivative security at price 5.35 per share.	10K	$53.50K
Jun 30, 2026	Wassil JamesChief Operating Officer	Sale at price 56.03 - 57.82 per share.	2.3K	$126.74K
Jun 30, 2026	Wassil JamesChief Operating Officer	Conversion of Exercise of derivative security at price 5.35 per share.	516	$2.76K

CONG

Congress Trades · PCVX

House and Senate reports since 2025

Members

1 last bought

Buys

~$48.0K

Sells

~$32.5K

Net

+$15.5K

est. bought − sold

Latest

Jul 16, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	6		+$48.0K	Bought Jul 16, 26
Jefferson Shreve IN06		1	−$32.5K	Sold Mar 5, 25

Bought and sold by quarter (est.)

Members of Congress's PCVX trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Jul 16, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Sep 4, 26 (50d)	PDF
May 13, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Jun 8, 26 (26d)	PDF
May 12, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Jun 8, 26 (27d)	PDF
Apr 28, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	May 6, 25 (8d)	PDF
Apr 15, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	May 6, 25 (21d)	PDF
Apr 14, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	May 6, 25 (22d)	PDF
Mar 5, 25	Jefferson Shreve IN06	Self	Sell	$15,001 - $50,000	Apr 11, 25 (37d)	PDF

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

13F

Investors Holding PCVX

latest 13F filings of 29 followed managers

Investors holding PCVX
Investor	Value	Of portfolio	Shares	Change	Quarter
Maverick Capital · Lee Ainslie	$93.8M	0.83%	1.61M	+17%	Q2 2026
Bridgewater Associates · Ray Dalio	$2.9M	0.01%	50.22K	+289%	Q2 2026
Renaissance Technologies	$1.1M	0.00%	19.63K	−64%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PCVX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PCVX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vaxcyte, Inc.

Seasonality · PCVX

Insider Activity · PCVX

Congress Trades · PCVX

Members who traded it

Bought and sold by quarter (est.)

Investors Holding PCVX

Investors Holding PCVX

Congress Trades · PCVX

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · PCVX

Seasonality · PCVX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vaxcyte, Inc.

Financial Snapshot

Earnings & Dividends

News